<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084136</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5175</org_study_id>
    <secondary_id>1U01AI068636</secondary_id>
    <secondary_id>PEARLS</secondary_id>
    <secondary_id>A5185s</secondary_id>
    <secondary_id>5K24AI051966-03</secondary_id>
    <nct_id>NCT00084136</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings</brief_title>
  <acronym>PEARLS</acronym>
  <official_title>Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared 3 different three-drug combinations in HIV infected individuals starting
      their first HIV treatment regimens. Participants were recruited from resource-limited areas
      in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis
      was each of the once daily combinations (PI based, or NNRTI based) would not have inferior
      efficacy compared to the twice daily NNRTI based combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In developed countries, standard effective antiretroviral (ARV) therapy for treatment-naive
      HIV infected people includes three-drug combinations of two nucleoside reverse transcriptase
      inhibitors (NRTIs) with either a protease inhibitor (PI) or a non-nucleoside reverse
      transcriptase inhibitor (NNRTI). However, direct comparisons of ARV efficacy in persons that
      more closely reflect the worldwide demographics of HIV-1 infection are needed.

      &gt;

      &gt; Trial participants were recruited in Africa (Malawi, South Africa, Zimbabwe), Asia (India,
      Thailand), South America (Brazil, Peru), Haiti, and the United States.

      &gt;

      &gt; All participants were randomly assigned to one of three arms, and random allocation was
      stratified by 2 factors: country, and screening plasma HIV-1 RNA level (&lt; 100,000 copies/mL
      versus &gt;= 100,000 copies/mL). Participants assigned to the ZDV/3TC+EFV arm received
      lamivudine/zidovudine twice daily and efavirenz once daily. Participants assigned to the
      ddI+FTC+ATV arm received emtricitabine, atazanavir, and enteric-coated didanosine once daily.
      Participants assigned to the TDF/FTC+EFV arm received emtricitabine, tenofovir disoproxil
      fumarate, and efavirenz once daily.

      &gt;

      &gt;

      &gt; Physical exam and blood collection occurred at entry and at most study visits. Participants
      experiencing virologic failure were offered a switch to another regimen.

      &gt;

      &gt; On May 23, 2008, the ddI+FTC+ATV was closed following a planned interim review by the
      study's independent Data and Safety Monitoring Board (DSMB). The DSMB recommendation was
      based upon compelling evidence that this arm had significantly more virologic failure (and
      therefore was inferior when) compared to the ZDV/3TC+EFV arm . Participants still receiving
      ddI+FTC+ATV were offered alternative medications, and all participants continued to be
      followed.

      &gt;

      &gt; On November 3, 2009, the DSMB recommended that the study close to all follow-up on May 31,
      2010, before the designed termination (based on 30% of participants meeting the primary
      outcome) was met. The board observed that the recent accumulation of primary efficacy events
      (i.e. regimen failures) was very slow. Therefore, if the study were to continue another 1-2
      years, the precision gained for treatment comparisons would likely be small.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Treatment Failure (PI Comparison)</measure>
    <time_frame>Virologic failure starting 14 weeks following randomization; disease progression starting 12 weeks following randomization; and death occurring at any time following randomization. Follow-up until ddI+FTC+ATV arm closed (May 22, 2008).</time_frame>
    <description>Time from randomization to the earliest of: scheduled week of first plasma sample meeting virologic failure (two consecutive plasma HIV-1 RNA values 1,000 copies/mL or higher, regardless of whether ARV medications being taken at the time); scheduled week of first AIDS defining diagnosis (WHO Stage 4 (2005), plus microsporidiosis, cyclospora gastroenteritis and Chaga's disease), not attributed to Immune Reconstitution Inflammatory Syndrome (reviewed by chairs); date of death (due to any cause). Plasma drawn every 8 weeks (except confirmation samples could be drawn earlier).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Treatment Failure (NRTI Comparison)</measure>
    <time_frame>Virologic failure starting 14 weeks following randomization; disease progression starting 12 weeks following randomization; and death occurring at any time following randomization. Follow-up through study closure (May 31, 2010).</time_frame>
    <description>Time from randomization to the earliest of: scheduled week of first plasma sample meeting virologic failure (two consecutive plasma HIV-1 RNA values 1,000 copies/mL or higher, regardless of whether ARV medications being taken at the time); scheduled week of first AIDS defining diagnosis (WHO Stage 4 (2005) plus microsporidiosis, cyclospora gastroenteritis and Chaga's disease), not attributed to Immune Reconstitution Inflammatory Syndrome (reviewed by chairs); date of death (due to any cause). Plasma drawn every 8 weeks (except confirmation samples could be drawn earlier).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (PI Comparison)</measure>
    <time_frame>Throughout follow-up until ddI+FTC+ATV arm closed (May 22,2008)</time_frame>
    <description>Time is measured from date of treatment initiation to earliest of the following: date of last participant contact (premature discontinuation of study follow-up); date all ARV medications were held (if all medications held for at least 8 weeks, for any reason); date that any ARV medication was changed (excluding the following single ARV substitutions: stavudine or tenofovir for zidovudine, nevirapine for efavirenz, or didanosine for tenofovir).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Immunologic Failure (PI Comparison)</measure>
    <time_frame>At or after Week 48 (including only follow-up until ddI+FTV+ATV arm closed - May 22,2008)</time_frame>
    <description>Time from randomization to the first scheduled study visit (week 48 or later) with a CD4+ cell count fewer than 100 cells/mm3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Count From Screening to Weeks 24, 48, 96 (PI Comparison)</measure>
    <time_frame>weeks 24, 48 and 96 (including follow-up until ddI+FTC+ARV arm closed - May 22, 2008)</time_frame>
    <description>Available pre-randomization CD4 cell counts were limited to the single CD4 cell count used for study eligibility (and therefore must have been fewer than 300 cells/mm3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose Modification or Grade 3 or 4 Adverse Event (PI Comparison)</measure>
    <time_frame>Throughout study follow-up until ddI+FTC+ATV arm closed (May 22, 2008)</time_frame>
    <description>Time from treatment dispensation to the first occurring of the following: week of first ARV medication change; week of first grade 3 or higher sign/symptom or laboratory abnormality (total bilirubin was excluded) that was at least one grade higher than baseline. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (PI Comparison)</measure>
    <time_frame>At Weeks 24 and 48 (including only follow-up until ddI+FTC+ARV arm closed - May 22, 2008)</time_frame>
    <description>Number of participants with plasma HIV-1 Viral load fewer than 400 copies/mL at study visit weeks 24 and 48. Closest observed result between 20 and up to 28 weeks (for week 24), and between 44 and up to 52 (for week 48) used if multiple results available. Missing values excluded, and both study treatment status and history ignored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(PI Comparison)</measure>
    <time_frame>Week 48 (using follow-up only until closing of ddI+FTV+ATV arm on May 22,2008)</time_frame>
    <description>Time from randomization to any of the following events occurring prior to week 48: discontinued ARV regimen (see time to discontinuation of initial ARV therapy above); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(PI Comparison)</measure>
    <time_frame>Week 48 (using follow-up only until closing of ddI+FTV+ATV arm on May 22,2008)</time_frame>
    <description>Time from randomization to any of the following events occurring prior to week 48: changed any ARV medication (including permanent discontinuation of all medications); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (NRTI Comparison)</measure>
    <time_frame>Throughout follow-up until study closed (May 31,2010)</time_frame>
    <description>Time is measured from date of treatment initiation to earliest of the following: date of last participant contact (premature discontinuation of study follow-up); date all ARV medications were held (if all medications held for at least 8 weeks, for any reason); date that any ARV medication was changed (excluding the following single ARV substitutions: stavudine or tenofovir for zidovudine, nevirapine for efavirenz, or didanosine for tenofovir).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Immunologic Failure (NRTI Comparison)</measure>
    <time_frame>At or after Week 48 (including all follow-up through study closure - May 31,2010)</time_frame>
    <description>Time from randomization to the first scheduled study visit (week 48 or later) with a CD4+ cell count fewer than 100 cells/mm3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Count From Screening to Weeks 24, 48, 96 (NRTI Comparison)</measure>
    <time_frame>weeks 24, 48 and 96 (including all follow-up through to study closure on May 31, 2010)</time_frame>
    <description>Available pre-randomization CD4 cell counts were limited to the single CD4 cell count used for study eligibility (and therefore must have been fewer than 300 cells/mm3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (NRTI Comparison)</measure>
    <time_frame>At Weeks 24 and 48 (including follow-up through to study closure on May 31, 2010)</time_frame>
    <description>Number of participants with plasma HIV-1 Viral load fewer than 400 copies/mL at study visit weeks 24 and 48. Closest observed result between 20 and up to 28 weeks (for week 24), and between 44 and up to 52 (for week 48) used if multiple results available. Missing values excluded, and both study treatment status and history ignored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)</measure>
    <time_frame>Week 48 (using follow-up through study closure on May 31,2010)</time_frame>
    <description>Time from randomization to any of the following events occurring prior to week 48: discontinued ARV regimen (see time to discontinuation of initial ARV therapy above); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)</measure>
    <time_frame>Week 96 (using follow-up through to study closure on May 31,2010)</time_frame>
    <description>Time from randomization to any of the following events occurring prior to week 96: discontinued ARV regimen (see time to discontinuation of initial ARV therapy above); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)</measure>
    <time_frame>Week 48 using follow-up through study closure on May 31,2010</time_frame>
    <description>Time from randomization to any of the following events occurring prior to week 48: changed any ARV medication (including permanent discontinuation of all medications); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)</measure>
    <time_frame>Week 96 using follow-up through study closure on May 31,2010</time_frame>
    <description>Time to any of the following events occurring prior to week 96: changed any ARV medication (including permanent discontinuation of all medications); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose Modification or Grade 3 or 4 Adverse Event (NRTI Comparison)</measure>
    <time_frame>Throughout study follow-up until study closure (May 31, 2010)</time_frame>
    <description>Time from treatment dispensation to the first occurring of the following: week of first ARV medication change; week of first grade 3 or higher sign/symptom or laboratory abnormality (total bilirubin was excluded) that was at least one grade higher than baseline. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1571</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>ZDV/3TC+EFV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ddI+FTC+ATV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF/FTC+EFV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>400 mg taken orally daily</description>
    <arm_group_label>ddI+FTC+ATV</arm_group_label>
    <other_name>ATV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine (enteric-coated)</intervention_name>
    <description>400 mg taken orally daily</description>
    <arm_group_label>ddI+FTC+ATV</arm_group_label>
    <other_name>ddI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>600 mg taken orally daily</description>
    <arm_group_label>ZDV/3TC+EFV</arm_group_label>
    <arm_group_label>TDF/FTC+EFV</arm_group_label>
    <other_name>EFV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>200 mg taken orally daily</description>
    <arm_group_label>ddI+FTC+ATV</arm_group_label>
    <other_name>FTC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/Tenofovir disoproxil fumarate</intervention_name>
    <description>200 mg/300 mg taken orally once daily</description>
    <arm_group_label>TDF/FTC+EFV</arm_group_label>
    <other_name>FTC/TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine/Zidovudine</intervention_name>
    <description>150 mg/300 mg taken orally twice daily</description>
    <arm_group_label>ZDV/3TC+EFV</arm_group_label>
    <other_name>3TC/ZDV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  HIV-1 infected

          -  CD4 count fewer than 300 cells/mm3

          -  Viral load test result

          -  Absolute Neutrophil Count at least 750mm3

          -  Hemoglobin at least 7.5 g/dL

          -  Platelet count at least 50,000/mm3

          -  Calculated creatinine clearance at least 60 mL/min

          -  A , A, and alkaline phosphatase &lt;= 5 times upper limit of normal

          -  total bilirubin &lt;= 2.5 times upper limit of normal

          -  Karnofsky performance score of 70 or higher

          -  Plans to stay in the area for the duration of the study

          -  Agrees to use acceptable forms of contraception for the duration of the study

        Exclusion Criteria:

          -  More than 7 days exposure to ARVs (except for single-dose NVP or ZDV for any period
             for the purpose of pMTCT)

          -  Acute therapy for serious medical illnesses within 14 days prior to study entry

          -  Certain abnormal laboratory values

          -  Radiation therapy or chemotherapy within 45 days prior to study entry.

          -  Any immunomodulator, HIV vaccine, or other investigational therapy within 30 days
             prior to study entry.

          -  Current alcohol or drug abuse that, in the opinion of the site investigator, would
             interfere with study participation

          -  Inflamed pancreas within 3 years prior to study entry

          -  Allergy/sensitivity to any of the study drugs or their formulations

          -  Heart rate less than 40 beats/min

          -  History of untreated, active second- or third-degree heart block

          -  Currently detained in jail or for treatment of a psychiatric or physical illness

          -  Vomiting or inability to swallow medications

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas B. Campbell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Flanigan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Miriam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Hakim, MscClinEpi, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medicine, University of Zimbabwe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nagalingeswaran Kumarasamy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for AIDS Research and Education</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor General/UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502-2052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Colorado Health Sciences Center, Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Hawaii at Manoa, Leahi Hosp.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816-2396</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush-Presbyterian/St. Lukes (Chicago)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hospital Core Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455-0392</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University (St. Louis)</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63108-2138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV Prevention &amp; Treatment CRS</name>
      <address>
        <city>HVTN 722 West 168th Street MSPH Bldg.</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Health Network, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake County Health and Human Services Clinical Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. of the Univ. of Pennsylvania CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanley Street Treatment and Resource</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hosp. ACTG CRS</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS</name>
      <address>
        <city>Manguinhos</city>
        <state>Rio de Janeiro</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Centres GHESKIO CRS</name>
      <address>
        <city>Bicentenaire</city>
        <state>Port-au-Prince</state>
        <zip>HT-6110</zip>
        <country>Haiti</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YRG CARE Medical Ctr., VHS Chennai CRS</name>
      <address>
        <city>Rajiv Gandhi Salai Taramani</city>
        <state>Chennai</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NARI Pune CRS</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NARI Clinic at NIV CRS</name>
      <address>
        <city>Maharashtra State</city>
        <state>Pune</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Kotnis Dispensary</name>
      <address>
        <city>Pune</city>
        <zip>411026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College of Med. JHU CRS</name>
      <address>
        <city>P.O. Box 1131</city>
        <state>Blantyre</state>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Lilongwe CRS</name>
      <address>
        <city>Mzimba Road</city>
        <state>Lilongwe</state>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asociacion Civil Impacta Salud y Educacion - Miraf CRS</name>
      <address>
        <city>Barranco</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Miguel CRS</name>
      <address>
        <city>San Miguel</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits HIV CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durban Adult HIV CRS</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai Univ. ACTG CRS</name>
      <address>
        <city>P.O. Box 80</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ-Parirenyatwa CRS</name>
      <address>
        <city>AIDS Research Unit P.O. Box A178</city>
        <state>Harare</state>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Haiti</country>
    <country>India</country>
    <country>Malawi</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United States</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <reference>
    <citation>Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, Griffith S, Irlbeck D, Shaefer MS; Clinically Significant Long-Term Antiretroviral Sequential Sequencing Study (CLASS) Team. Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):284-92.</citation>
    <PMID>16967040</PMID>
  </reference>
  <reference>
    <citation>Saag MS. Initiation of antiretroviral therapy: implications of recent findings. Top HIV Med. 2004 Jul-Aug;12(3):83-8. Review.</citation>
    <PMID>15310939</PMID>
  </reference>
  <reference>
    <citation>Tapper ML, Daar ES, Piliero PJ, Smith K, Steinhart C. Strategies for initiating combination antiretroviral therapy. AIDS Patient Care STDS. 2005 Apr;19(4):224-38. Review.</citation>
    <PMID>15857194</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2004</study_first_submitted>
  <study_first_submitted_qc>June 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2004</study_first_posted>
  <results_first_submitted>July 13, 2011</results_first_submitted>
  <results_first_submitted_qc>July 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2011</results_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Naive</keyword>
  <keyword>Adherence</keyword>
  <keyword>Drug Resistance</keyword>
  <keyword>Treatment Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited at 43 sites from 9 countries: 28 in the US, 4 in India, 2 each in Brazil, Malawi, Peru and South Africa, and 1 each in Haiti, Thailand and Zimbabwe, between May 2005 to August 2007.</recruitment_details>
      <pre_assignment_details>HIV-infected, treatment-naive men and women, at least 18 years of age with CD4+ count &lt;300 cells/mm^3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ZDV/3TC+EFV</title>
          <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
        </group>
        <group group_id="P2">
          <title>ddI+FTC+ATV</title>
          <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine &gt;
&gt; On May 23, 2008, Arm B was closed following a planned interim review by the study's independent Data and Safety Monitoring Board (DSMB). The DSMB recommendation was based upon compelling evidence that Arm B had significantly more virologic failure (and therefore was inferior when) compared to Arm A. Participants still receiving Arm B medications were offered alternatives, and all participants continued to be followed.</description>
        </group>
        <group group_id="P3">
          <title>TDF/FTC+EFV</title>
          <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>PI Comparison</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="519"/>
                <participants group_id="P2" count="526"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="464">Follow-up was until ddI+FTC+ATV arm was closed per DSMB recommendation on May 23, 2008.</participants>
                <participants group_id="P2" count="479">Follow-up was until ddI+FTC+ATV arm was closed per DSMB recommendation on May 23, 2008.</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinic site closed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>NRTI Comparison</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="519"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="526"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="418">Follow-up though study closeout period (final visit between April 1 and May 31, 2010).</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="444">Follow-up though study closeout period (final visit between April 1 and May 31, 2010).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinic site closed</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not reason above</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ZDV/3TC+EFV</title>
          <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
        </group>
        <group group_id="B2">
          <title>ddI+FTC+ATV</title>
          <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine &gt;
&gt; On May 23, 2008, Arm B was closed following a planned interim review by the study's independent Data and Safety Monitoring Board (DSMB). The DSMB recommendation was based upon compelling evidence that Arm B had significantly more virologic failure (and therefore was inferior when) compared to Arm A. Participants still receiving Arm B medications were offered alternatives, and all participants continued to be followed.</description>
        </group>
        <group group_id="B3">
          <title>TDF/FTC+EFV</title>
          <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="519"/>
            <count group_id="B2" value="526"/>
            <count group_id="B3" value="526"/>
            <count group_id="B4" value="1571"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="9"/>
                    <measurement group_id="B2" value="35" spread="8"/>
                    <measurement group_id="B3" value="35" spread="9"/>
                    <measurement group_id="B4" value="35" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 30 and 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="225"/>
                    <measurement group_id="B4" value="690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 40 and 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="242"/>
                    <measurement group_id="B4" value="739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="284"/>
                    <measurement group_id="B4" value="832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haiti</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malawi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zimbabwe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 count, Continuous</title>
          <description>Screening value used for study eligibility as no other pre-randomization CD4 cell counts available</description>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163" spread="85"/>
                    <measurement group_id="B2" value="167" spread="83"/>
                    <measurement group_id="B3" value="155" spread="81"/>
                    <measurement group_id="B4" value="162" spread="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 count, Categorical</title>
          <description>Screening CD4 count used for study eligibility as no other pre-randomization counts available.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 50 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 50 and 99 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 100 and 199 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="193"/>
                    <measurement group_id="B4" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 200 and 249 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 250 and 299 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV-1 RNA, Continuous</title>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" lower_limit="4.6" upper_limit="5.4"/>
                    <measurement group_id="B2" value="5.1" lower_limit="4.5" upper_limit="5.5"/>
                    <measurement group_id="B3" value="5.0" lower_limit="4.5" upper_limit="5.5"/>
                    <measurement group_id="B4" value="5.0" lower_limit="4.6" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV-1 RNA, Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 400 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 400 and 4000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 4001 and 40,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 40,001 and 400,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="311"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="284"/>
                    <measurement group_id="B4" value="878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 400,001 and 749,999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 750,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Treatment Failure (PI Comparison)</title>
        <description>Time from randomization to the earliest of: scheduled week of first plasma sample meeting virologic failure (two consecutive plasma HIV-1 RNA values 1,000 copies/mL or higher, regardless of whether ARV medications being taken at the time); scheduled week of first AIDS defining diagnosis (WHO Stage 4 (2005), plus microsporidiosis, cyclospora gastroenteritis and Chaga's disease), not attributed to Immune Reconstitution Inflammatory Syndrome (reviewed by chairs); date of death (due to any cause). Plasma drawn every 8 weeks (except confirmation samples could be drawn earlier).</description>
        <time_frame>Virologic failure starting 14 weeks following randomization; disease progression starting 12 weeks following randomization; and death occurring at any time following randomization. Follow-up until ddI+FTC+ATV arm closed (May 22, 2008).</time_frame>
        <population>ITT (study treatment status and history ignored); censoring time was latest study visit week where plasma HIV-1 RNA was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (PI Comparison)</title>
          <description>Time from randomization to the earliest of: scheduled week of first plasma sample meeting virologic failure (two consecutive plasma HIV-1 RNA values 1,000 copies/mL or higher, regardless of whether ARV medications being taken at the time); scheduled week of first AIDS defining diagnosis (WHO Stage 4 (2005), plus microsporidiosis, cyclospora gastroenteritis and Chaga's disease), not attributed to Immune Reconstitution Inflammatory Syndrome (reviewed by chairs); date of death (due to any cause). Plasma drawn every 8 weeks (except confirmation samples could be drawn earlier).</description>
          <population>ITT (study treatment status and history ignored); censoring time was latest study visit week where plasma HIV-1 RNA was measured.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O2" value="16" lower_limit="16" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="24" upper_limit="64"/>
                    <measurement group_id="O2" value="24" lower_limit="16" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="152">Not estimable as the estimate for survival function at all weeks is above 75%</measurement>
                    <measurement group_id="O2" value="120" lower_limit="96">Not estimable as the upper limit for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Not adjusted for multiple interim analyses. Peto-Haybittle spending function was used as a basis for calculating the repeated confidence intervals used in interim monitoring.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Log-rank test was stratified by country and screening RNA (&lt; 100,000 c/mL vs &gt;= 100,000 copies/mL).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
            <estimate_desc>The HR is for ddI+FTC+ATV vs. ZDV/3TC+EFV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Treatment Failure (NRTI Comparison)</title>
        <description>Time from randomization to the earliest of: scheduled week of first plasma sample meeting virologic failure (two consecutive plasma HIV-1 RNA values 1,000 copies/mL or higher, regardless of whether ARV medications being taken at the time); scheduled week of first AIDS defining diagnosis (WHO Stage 4 (2005) plus microsporidiosis, cyclospora gastroenteritis and Chaga's disease), not attributed to Immune Reconstitution Inflammatory Syndrome (reviewed by chairs); date of death (due to any cause). Plasma drawn every 8 weeks (except confirmation samples could be drawn earlier).</description>
        <time_frame>Virologic failure starting 14 weeks following randomization; disease progression starting 12 weeks following randomization; and death occurring at any time following randomization. Follow-up through study closure (May 31, 2010).</time_frame>
        <population>ITT (study treatment status and history ignored); censoring time was latest study visit week where plasma HIV-1 RNA was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (NRTI Comparison)</title>
          <description>Time from randomization to the earliest of: scheduled week of first plasma sample meeting virologic failure (two consecutive plasma HIV-1 RNA values 1,000 copies/mL or higher, regardless of whether ARV medications being taken at the time); scheduled week of first AIDS defining diagnosis (WHO Stage 4 (2005) plus microsporidiosis, cyclospora gastroenteritis and Chaga's disease), not attributed to Immune Reconstitution Inflammatory Syndrome (reviewed by chairs); date of death (due to any cause). Plasma drawn every 8 weeks (except confirmation samples could be drawn earlier).</description>
          <population>ITT (study treatment status and history ignored); censoring time was latest study visit week where plasma HIV-1 RNA was measured.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O3" value="16" lower_limit="16" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="24" upper_limit="71"/>
                    <measurement group_id="O3" value="40" lower_limit="24" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="224">Not estimable as the estimate for survival function at all weeks is above 75%</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="216">Not estimable as the estimate for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>While original study design specified a non-inferiority test, study follow-up stopped early, not due to treatment effect size or futility, but due to slowing accumulation of primary outcome events. Therefore, 2-sided, 95% confidence intervals about the estimated treatment effect (relative effect estimated by a hazard ratio) are provided.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>The HR is for TDF/FTC+EFV vs. ZDV/3TC+EFV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (PI Comparison)</title>
        <description>Time is measured from date of treatment initiation to earliest of the following: date of last participant contact (premature discontinuation of study follow-up); date all ARV medications were held (if all medications held for at least 8 weeks, for any reason); date that any ARV medication was changed (excluding the following single ARV substitutions: stavudine or tenofovir for zidovudine, nevirapine for efavirenz, or didanosine for tenofovir).</description>
        <time_frame>Throughout follow-up until ddI+FTC+ATV arm closed (May 22,2008)</time_frame>
        <population>Participants not starting study treatment excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (PI Comparison)</title>
          <description>Time is measured from date of treatment initiation to earliest of the following: date of last participant contact (premature discontinuation of study follow-up); date all ARV medications were held (if all medications held for at least 8 weeks, for any reason); date that any ARV medication was changed (excluding the following single ARV substitutions: stavudine or tenofovir for zidovudine, nevirapine for efavirenz, or didanosine for tenofovir).</description>
          <population>Participants not starting study treatment excluded.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="522"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="8" upper_limit="22"/>
                    <measurement group_id="O2" value="7" lower_limit="3" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="24" upper_limit="46"/>
                    <measurement group_id="O2" value="18" lower_limit="12" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not estimable as the estimates for survival function at all weeks is above 75%</measurement>
                    <measurement group_id="O2" value="76" lower_limit="50">Not estimable as the upper limit for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Immunologic Failure (PI Comparison)</title>
        <description>Time from randomization to the first scheduled study visit (week 48 or later) with a CD4+ cell count fewer than 100 cells/mm3.</description>
        <time_frame>At or after Week 48 (including only follow-up until ddI+FTV+ATV arm closed - May 22,2008)</time_frame>
        <population>ITT (ignoring current study treatment status or history)</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Immunologic Failure (PI Comparison)</title>
          <description>Time from randomization to the first scheduled study visit (week 48 or later) with a CD4+ cell count fewer than 100 cells/mm3.</description>
          <population>ITT (ignoring current study treatment status or history)</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="48" upper_limit="48"/>
                    <measurement group_id="O2" value="48" lower_limit="48" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" lower_limit="48">Not estimable as the upper limit for survival function at all weeks is above 5%</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="64">Not estimable as the estimate for survival function at all weeks is above 5%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Count From Screening to Weeks 24, 48, 96 (PI Comparison)</title>
        <description>Available pre-randomization CD4 cell counts were limited to the single CD4 cell count used for study eligibility (and therefore must have been fewer than 300 cells/mm3).</description>
        <time_frame>weeks 24, 48 and 96 (including follow-up until ddI+FTC+ARV arm closed - May 22, 2008)</time_frame>
        <population>ITT - ignoring both current treatment status and treatment history.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine &gt;
&gt; On May 23, 2008, Arm B was closed following a planned interim review by the study's independent Data and Safety Monitoring Board (DSMB). The DSMB recommendation was based upon compelling evidence that Arm B had significantly more virologic failure (and therefore was inferior when) compared to Arm A. Participants still receiving Arm B medications were offered alternatives, and all participants continued to be followed.</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Count From Screening to Weeks 24, 48, 96 (PI Comparison)</title>
          <description>Available pre-randomization CD4 cell counts were limited to the single CD4 cell count used for study eligibility (and therefore must have been fewer than 300 cells/mm3).</description>
          <population>ITT - ignoring both current treatment status and treatment history.</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from screening to week 24 (N=490; N=502)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.5" lower_limit="57.0" upper_limit="185.0"/>
                    <measurement group_id="O2" value="146.5" lower_limit="79.0" upper_limit="224.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from screening to week 48 (N=474; N=477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.0" lower_limit="84.0" upper_limit="236.0"/>
                    <measurement group_id="O2" value="187.0" lower_limit="111.0" upper_limit="272.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from screening to week 96 (N= 188; N=188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.0" lower_limit="149.0" upper_limit="300.5"/>
                    <measurement group_id="O2" value="256.0" lower_limit="142.5" upper_limit="371.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Dose Modification or Grade 3 or 4 Adverse Event (PI Comparison)</title>
        <description>Time from treatment dispensation to the first occurring of the following: week of first ARV medication change; week of first grade 3 or higher sign/symptom or laboratory abnormality (total bilirubin was excluded) that was at least one grade higher than baseline. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables.</description>
        <time_frame>Throughout study follow-up until ddI+FTC+ATV arm closed (May 22, 2008)</time_frame>
        <population>Participants never starting meds excluded. Censoring time is scheduled study week of last clinic visit.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Dose Modification or Grade 3 or 4 Adverse Event (PI Comparison)</title>
          <description>Time from treatment dispensation to the first occurring of the following: week of first ARV medication change; week of first grade 3 or higher sign/symptom or laboratory abnormality (total bilirubin was excluded) that was at least one grade higher than baseline. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables.</description>
          <population>Participants never starting meds excluded. Censoring time is scheduled study week of last clinic visit.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="522"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="12" upper_limit="16"/>
                    <measurement group_id="O2" value="32" lower_limit="20" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="72" upper_limit="144"/>
                    <measurement group_id="O2" value="144" lower_limit="120">Not estimable as the upper limit for survival function at all weeks is above 50%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (PI Comparison)</title>
        <description>Number of participants with plasma HIV-1 Viral load fewer than 400 copies/mL at study visit weeks 24 and 48. Closest observed result between 20 and up to 28 weeks (for week 24), and between 44 and up to 52 (for week 48) used if multiple results available. Missing values excluded, and both study treatment status and history ignored.</description>
        <time_frame>At Weeks 24 and 48 (including only follow-up until ddI+FTC+ARV arm closed - May 22, 2008)</time_frame>
        <population>ITT (ignoring current treatment status or past treatment history); closest value to week 24 (48) used if multiple values available; missing values ignored.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine &gt;
&gt; On May 23, 2008, Arm B was closed following a planned interim review by the study's independent Data and Safety Monitoring Board (DSMB). The DSMB recommendation was based upon compelling evidence that Arm B had significantly more virologic failure (and therefore was inferior when) compared to Arm A. Participants still receiving Arm B medications were offered alternatives, and all participants continued to be followed.</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (PI Comparison)</title>
          <description>Number of participants with plasma HIV-1 Viral load fewer than 400 copies/mL at study visit weeks 24 and 48. Closest observed result between 20 and up to 28 weeks (for week 24), and between 44 and up to 52 (for week 48) used if multiple results available. Missing values excluded, and both study treatment status and history ignored.</description>
          <population>ITT (ignoring current treatment status or past treatment history); closest value to week 24 (48) used if multiple values available; missing values ignored.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24: Number with RNA &lt;400 c/mL (N=495; N=506)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459"/>
                    <measurement group_id="O2" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Number with RNA &lt;400 c/mL (N=476; N=478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437"/>
                    <measurement group_id="O2" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(PI Comparison)</title>
        <description>Time from randomization to any of the following events occurring prior to week 48: discontinued ARV regimen (see time to discontinuation of initial ARV therapy above); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
        <time_frame>Week 48 (using follow-up only until closing of ddI+FTV+ATV arm on May 22,2008)</time_frame>
        <population>Substitutions not triggering TLOVR event included the following: stavudine or tenofovir-DF for zidovudine; nevirapine for efavirenz; or didanosine for tenofovir-DF.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(PI Comparison)</title>
          <description>Time from randomization to any of the following events occurring prior to week 48: discontinued ARV regimen (see time to discontinuation of initial ARV therapy above); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
          <population>Substitutions not triggering TLOVR event included the following: stavudine or tenofovir-DF for zidovudine; nevirapine for efavirenz; or didanosine for tenofovir-DF.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="8" upper_limit="32"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not estimable as the estimates for survival function at all weeks is above 75%</measurement>
                    <measurement group_id="O2" value="48" lower_limit="32">Not estimable as the upper limit for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(PI Comparison)</title>
        <description>Time from randomization to any of the following events occurring prior to week 48: changed any ARV medication (including permanent discontinuation of all medications); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
        <time_frame>Week 48 (using follow-up only until closing of ddI+FTV+ATV arm on May 22,2008)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(PI Comparison)</title>
          <description>Time from randomization to any of the following events occurring prior to week 48: changed any ARV medication (including permanent discontinuation of all medications); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="16" upper_limit="48"/>
                    <measurement group_id="O2" value="48" lower_limit="32">Not estimable as the upper limit for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (NRTI Comparison)</title>
        <description>Time is measured from date of treatment initiation to earliest of the following: date of last participant contact (premature discontinuation of study follow-up); date all ARV medications were held (if all medications held for at least 8 weeks, for any reason); date that any ARV medication was changed (excluding the following single ARV substitutions: stavudine or tenofovir for zidovudine, nevirapine for efavirenz, or didanosine for tenofovir).</description>
        <time_frame>Throughout follow-up until study closed (May 31,2010)</time_frame>
        <population>Participants not starting study treatment excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (NRTI Comparison)</title>
          <description>Time is measured from date of treatment initiation to earliest of the following: date of last participant contact (premature discontinuation of study follow-up); date all ARV medications were held (if all medications held for at least 8 weeks, for any reason); date that any ARV medication was changed (excluding the following single ARV substitutions: stavudine or tenofovir for zidovudine, nevirapine for efavirenz, or didanosine for tenofovir).</description>
          <population>Participants not starting study treatment excluded.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="8" upper_limit="23"/>
                    <measurement group_id="O3" value="18" lower_limit="8" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="24" upper_limit="45"/>
                    <measurement group_id="O3" value="36" lower_limit="24" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163" lower_limit="120" upper_limit="200"/>
                    <measurement group_id="O3" value="201" lower_limit="160">Not estimable as the upper limit for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Immunologic Failure (NRTI Comparison)</title>
        <description>Time from randomization to the first scheduled study visit (week 48 or later) with a CD4+ cell count fewer than 100 cells/mm3.</description>
        <time_frame>At or after Week 48 (including all follow-up through study closure - May 31,2010)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Immunologic Failure (NRTI Comparison)</title>
          <description>Time from randomization to the first scheduled study visit (week 48 or later) with a CD4+ cell count fewer than 100 cells/mm3.</description>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="48" upper_limit="48"/>
                    <measurement group_id="O3" value="48" lower_limit="48" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="48">Not estimable as the upper limit for survival function at all weeks is above 95%</measurement>
                    <measurement group_id="O3" value="104" lower_limit="48">Not estimable as the upper limit for survival function at all weeks is above 95%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="248">Not estimable as the estimates for survival function at all weeks is above 90%</measurement>
                    <measurement group_id="O3" value="NA">Not estimable as all estimates for survival function at all weeks is above 90%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Count From Screening to Weeks 24, 48, 96 (NRTI Comparison)</title>
        <description>Available pre-randomization CD4 cell counts were limited to the single CD4 cell count used for study eligibility (and therefore must have been fewer than 300 cells/mm3).</description>
        <time_frame>weeks 24, 48 and 96 (including all follow-up through to study closure on May 31, 2010)</time_frame>
        <population>ITT - ignoring both current treatment status and treatment history.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Count From Screening to Weeks 24, 48, 96 (NRTI Comparison)</title>
          <description>Available pre-randomization CD4 cell counts were limited to the single CD4 cell count used for study eligibility (and therefore must have been fewer than 300 cells/mm3).</description>
          <population>ITT - ignoring both current treatment status and treatment history.</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from screening to week 24 (N=490; N=498)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.5" lower_limit="57" upper_limit="185"/>
                    <measurement group_id="O3" value="120.5" lower_limit="67" upper_limit="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from screening to week 48 (N=480; N=485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.5" lower_limit="84" upper_limit="233.5"/>
                    <measurement group_id="O3" value="159" lower_limit="97" upper_limit="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from screening to week 96 (N=458; N=471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.5" lower_limit="143" upper_limit="313"/>
                    <measurement group_id="O3" value="226" lower_limit="142" upper_limit="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (NRTI Comparison)</title>
        <description>Number of participants with plasma HIV-1 Viral load fewer than 400 copies/mL at study visit weeks 24 and 48. Closest observed result between 20 and up to 28 weeks (for week 24), and between 44 and up to 52 (for week 48) used if multiple results available. Missing values excluded, and both study treatment status and history ignored.</description>
        <time_frame>At Weeks 24 and 48 (including follow-up through to study closure on May 31, 2010)</time_frame>
        <population>ITT (ignoring current treatment status or past treatment history); closest value to week 24 (48) used if multiple values available; missing values ignored.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (NRTI Comparison)</title>
          <description>Number of participants with plasma HIV-1 Viral load fewer than 400 copies/mL at study visit weeks 24 and 48. Closest observed result between 20 and up to 28 weeks (for week 24), and between 44 and up to 52 (for week 48) used if multiple results available. Missing values excluded, and both study treatment status and history ignored.</description>
          <population>ITT (ignoring current treatment status or past treatment history); closest value to week 24 (48) used if multiple values available; missing values ignored.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24: Number with RNA &lt;400 c/mL (N=495; N=500)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459"/>
                    <measurement group_id="O3" value="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Number with RNA &lt;400 c/mL (N=482; N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442"/>
                    <measurement group_id="O3" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)</title>
        <description>Time from randomization to any of the following events occurring prior to week 48: discontinued ARV regimen (see time to discontinuation of initial ARV therapy above); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
        <time_frame>Week 48 (using follow-up through study closure on May 31,2010)</time_frame>
        <population>Substitutions not triggering TLOVR event included the following: stavudine or tenofovir-DF for zidovudine; nevirapine for efavirenz; or didanosine for tenofovir-DF.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)</title>
          <description>Time from randomization to any of the following events occurring prior to week 48: discontinued ARV regimen (see time to discontinuation of initial ARV therapy above); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
          <population>Substitutions not triggering TLOVR event included the following: stavudine or tenofovir-DF for zidovudine; nevirapine for efavirenz; or didanosine for tenofovir-DF.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="0" upper_limit="32"/>
                    <measurement group_id="O3" value="24" lower_limit="0" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)</title>
        <description>Time from randomization to any of the following events occurring prior to week 96: discontinued ARV regimen (see time to discontinuation of initial ARV therapy above); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
        <time_frame>Week 96 (using follow-up through to study closure on May 31,2010)</time_frame>
        <population>Substitutions not triggering TLOVR event included the following: stavudine or tenofovir-DF for zidovudine; nevirapine for efavirenz; or didanosine for tenofovir-DF.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)</title>
          <description>Time from randomization to any of the following events occurring prior to week 96: discontinued ARV regimen (see time to discontinuation of initial ARV therapy above); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
          <population>Substitutions not triggering TLOVR event included the following: stavudine or tenofovir-DF for zidovudine; nevirapine for efavirenz; or didanosine for tenofovir-DF.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="0" upper_limit="32"/>
                    <measurement group_id="O3" value="24" lower_limit="0" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="88">Not estimable as the estimates for survival function at all weeks is above 75%</measurement>
                    <measurement group_id="O3" value="NA">Not estimable as all estimates for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)</title>
        <description>Time from randomization to any of the following events occurring prior to week 48: changed any ARV medication (including permanent discontinuation of all medications); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
        <time_frame>Week 48 using follow-up through study closure on May 31,2010</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)</title>
          <description>Time from randomization to any of the following events occurring prior to week 48: changed any ARV medication (including permanent discontinuation of all medications); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="16" upper_limit="48"/>
                    <measurement group_id="O3" value="NA">Not estimable as all estimates for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)</title>
        <description>Time to any of the following events occurring prior to week 96: changed any ARV medication (including permanent discontinuation of all medications); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
        <time_frame>Week 96 using follow-up through study closure on May 31,2010</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)</title>
          <description>Time to any of the following events occurring prior to week 96: changed any ARV medication (including permanent discontinuation of all medications); discontinued study follow-up or died; absence of virologic suppression defined as 2 consecutive plasma HIV-1 RNA values &lt; 400 copies/mL; two consecutive plasma HIV-1 RNA values &gt; 400 copies/mL following virologic suppression.</description>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="16" upper_limit="56"/>
                    <measurement group_id="O3" value="NA" lower_limit="80">Not estimable as the estimates for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Dose Modification or Grade 3 or 4 Adverse Event (NRTI Comparison)</title>
        <description>Time from treatment dispensation to the first occurring of the following: week of first ARV medication change; week of first grade 3 or higher sign/symptom or laboratory abnormality (total bilirubin was excluded) that was at least one grade higher than baseline. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables.</description>
        <time_frame>Throughout study follow-up until study closure (May 31, 2010)</time_frame>
        <population>Participants never starting meds excluded. Censoring time is scheduled study week of last clinic visit.</population>
        <group_list>
          <group group_id="O1">
            <title>ZDV/3TC+EFV</title>
            <description>ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz</description>
          </group>
          <group group_id="O2">
            <title>ddI+FTC+ATV</title>
            <description>ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine</description>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+EFV</title>
            <description>TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Dose Modification or Grade 3 or 4 Adverse Event (NRTI Comparison)</title>
          <description>Time from treatment dispensation to the first occurring of the following: week of first ARV medication change; week of first grade 3 or higher sign/symptom or laboratory abnormality (total bilirubin was excluded) that was at least one grade higher than baseline. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables.</description>
          <population>Participants never starting meds excluded. Censoring time is scheduled study week of last clinic visit.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="12" upper_limit="16"/>
                    <measurement group_id="O3" value="32" lower_limit="24" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" lower_limit="72" upper_limit="136"/>
                    <measurement group_id="O3" value="224" lower_limit="192">Not estimable as the upper limit for survival function at all weeks is above 50%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout study follow-up (until May 31, 2010 or earlier only if participant prematurely left the study).</time_frame>
      <desc>Standard Level reporting by DAIDS EAE Manual,May 6, 2004(http://rcc.tech-res.com/safetyandpharmacovigilance/). ATV-related, asymptomatic hyperbilirubinemia or jaundice without LFT elevation does not require (EAE) reporting. IRIS events do not fulfill the DAIDS EAE reporting criteria, even if the event is severe in intensity.</desc>
      <group_list>
        <group group_id="E1">
          <title>ZDV/3TC+EFV</title>
        </group>
        <group group_id="E2">
          <title>ddI+FTC+ATV</title>
        </group>
        <group group_id="E3">
          <title>TDF/FTC+EFV</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Bone marrow toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS related complex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Abortion infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Chikungunya virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Corynebacterium sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Cranial nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dapsone syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="481" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="521" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="489" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="261" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="265" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="269" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="304" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="289" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood albumin abnormal</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="188" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate abnormal</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="397" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased vibratory sense</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="526"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="519"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="526"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinicaltrials.gov Coordinator</name_or_title>
      <organization>Center for Biostatistics in AIDS Research, Harvard School of Public Health</organization>
      <phone>617-432-2829</phone>
      <email>CBAR.ClinicalTrials.Gov@sdac.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

